SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001404644-24-000086
Filing Date
2024-08-09
Accepted
2024-08-09 16:15:03
Documents
78
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ngne-20240630.htm   iXBRL 10-Q 1509773
2 EX-31.1 ngne-2024formq210xqxex311p.htm EX-31.1 9564
3 EX-31.2 ngne-2024formq210xqxex312p.htm EX-31.2 9694
4 EX-32.1 ngne-2024formq210xqxex321.htm EX-32.1 7267
  Complete submission text file 0001404644-24-000086.txt   6905151

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20240630.xsd EX-101.SCH 46036
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ngne-20240630_cal.xml EX-101.CAL 70450
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ngne-20240630_def.xml EX-101.DEF 194105
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20240630_lab.xml EX-101.LAB 620750
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20240630_pre.xml EX-101.PRE 436940
81 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20240630_htm.xml XML 803830
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 980542593 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36327 | Film No.: 241192960
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)